Source: https://www.newsgram.com/vaccine-treating-alzheimers-disease
A preventive treatment for Dementia Disease may proceed to
clinical trials after successful animal testing, say researchers..
The research is looking to develop effective immunotherapy
via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to
Alzheimer’s disease. Recent success in bigenic mice models supports progression
to human trials in years to come, the research added. The study, published in
the journal Alzheimer’s Research & Therapy paves the way for more work in
2020 ith medical researchers at the Institute for Molecular Medicine and
University of California, Irvine (UCI) working with a successful vaccine
formulated on adjuvant developed by Flinders University Professor Nikolai
Petrovsky in Australia. The researchers tested the universal MultiTEP
platform-based vaccines formulated in the adjuvant developed at Australian lab.
The possible new therapies were tested in bigenic mice with mix and tau
pathologies.
“Taken together, these findings warrant further development
of this dual vaccination strategy based on the MultiTEP technology for ultimate
testing in human Alzheimer’s disease,” said the study lead authors Professor
Anahit Ghochikyan and Mathew Blurton-Jones. Professor Petrovsky said the Advax
adjuvant method is a pivotal system to help take the combination MultiTEP-based
A�/tau vaccines therapy, as well as separate vaccines targeting these
pathological molecules, to clinical trials – perhaps within two years. “Our
approach is looking to cover all bases and get past previous roadblocks in
finding a therapy to slow the accumulation of A�/tau molecules and delay
Alzheimer’s disease progression in a the rising number of people around the
world,” Petrovsky added. Several promising drug candidates have failed in
clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab,
showed that high dose of this antibody reduced clinical decline in patients
with early Alzheimer’s disease as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a
preventive measure in healthy subjects due to the need for frequent (monthly)
administration of high concentrations of immunotherapeutic. There is a pressing
need to keep searching for new preventive vaccine to delay Alzheimer’s disease
and slow down progression of this devastating disease..
